# Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT02277769** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 708 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo (for Dupilumab)

## Key facts

- **NCT ID:** NCT02277769
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-30
- **Primary completion:** 2015-10-31
- **Final completion:** 2016-01-31
- **Target enrollment:** 708 (ACTUAL)
- **Last updated:** 2020-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277769, "Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02277769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*